Biosimilar ‘skinny labels’ saved Medicare $1.5B, study shows

From 2015 to 2020, FDA approvals of “skinny labels” on biosimilars saved Medicare $1.5 billion, according to a study published Nov. 28 in the Journal of the American Medical Association. 

Read the full post on Becker's Hospital Review - Healthcare News